Work Here?
Overview
Future House is a non-profit that develops semi-autonomous AI agents to accelerate scientific research in biology and biochemistry. Its offerings include AI tools and assistants that help researchers perform scientific tasks, such as planning experiments, analyzing data, and reviewing literature, by automating parts of the scientific method under human guidance. The company differentiates itself by combining AI and biology expertise through fellowship programs that enable young researchers to use and improve the AI tools, with a focus on open collaboration and worldwide access. Its goal is to speed up discoveries and broaden access to advanced scientific tools and knowledge for researchers around the world.
About FutureHouse
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Education
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2023
Get referred to FutureHouse
See people who can refer or advise you
Simplify's Take
What believers are saying
- Nature publication on May 19, 2026 gives Robin immediate legitimacy with scientists and funders.
- June 4, 2026 platform launch opened public access to superhuman literature search and synthesis.
- The macular-degeneration discovery shows automated agents can generate testable biology, strengthening fellowship recruiting.
What critics are saying
- FutureHouse depends on Schmidt, Open Philanthropy, NSF, and AI Safety Institute funding.
- Phoenix remains experimental on June 4, 2026, and FutureHouse admits it makes more mistakes.
- Robin’s macular-degeneration result is cell-based, not clinical; reproducibility failures would kill credibility and adoption.
What makes FutureHouse unique
- Robin, published in Nature on May 19, 2026, automates hypothesis-to-validation discovery end-to-end.
- FutureHouse’s platform bundles Crow, Falcon, Owl, and Phoenix for science-specific literature and chemistry tasks.
- Its nonprofit model and fellowship program attract researchers without VC-style pressure for near-term revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 16%1 year growth
↑ 16%2 year growth
↑ 16%Two AI systems, Robin and Crow, developed by FutureHouse, have successfully completed drug-retargeting tasks for macular degeneration. Robin formed hypotheses about disease mechanisms, suggested cell lines and culture conditions, and evaluated 30 candidate drugs through automated reports reviewed by human experts. The system includes Finch, a tool that automates evaluation of biological screening assays like flow cytometry and RNA-seq. Robin identified a novel hypothesis that increasing retinal cells' ability to clear debris could protect against the disease and found a drug providing that effect. Tools designed for scientific literature proved crucial. Replacing Crow with OpenAI's o4-mini increased hallucinated references from zero to 45 percent. When compared to OpenAI's research-focused tool, all drugs it suggested that Robin hadn't identified failed to affect cells.
The AI platform for scientific R&D. Spun out from @FutureHouseSF to accelerate research and innovation in science.
FutureHouse launched a closed beta for Finch, its AI tool for 'data-driven discovery'
With the launch of Finch, an AI tool designed to process biological data, FutureHouse aims to assist researchers in generating insights akin to those produced by first-year graduate students.
FutureHouse released four AI tools named Crow, Falcon, Owl, and Phoenix.
There are no jobs for FutureHouse right now.
Find jobs on Simplify and start your career today
About FutureHouse
Industries
Data & Analytics
AI & Machine Learning
Biotechnology
Education
Company Size
11-50
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2023
There are no jobs for FutureHouse right now.
Find jobs on Simplify and start your career today